Saturday, October 3, 2026

USD/CNH Over 1% Down In The Last 10 Sessions

ViaNews Editorial Team

January 29, 2024

USD/CNH Over 1% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.9% for the last 10 sessions. At 02:11 EST on Monday, 29 January, USD/CNH (USDCNH) is $7.19.

USD/CNH's yearly highs and lows, it's 0.118% up from its 52-week low and 0.085% down from its 52-week high.

News about

  • Eur/usd weekly forecast: incremental trend lower persists as traders fret - 28 January 2024. According to DailyForex on Sunday, 28 January, "Speculators should not be surprised if the EUR/USD touches the 1.08100 to 1.07950 marks below as lower support levels.", "The EUR/USD went into the weekend near the 1.08530 mark which is slightly above the low it produced on Friday around the 1.08120 ratio."
  • Eur/usd remains under pressure below 1.0850, German GDP data eyed. According to FXStreet on Monday, 29 January, "This, in turn, might exert some selling on the Euro (EUR) and act as a headwind for the EUR/USD pair."
  • Eur/usd price analysis: inches lower to 1.0840 followed by the monthly low. According to FXStreet on Monday, 29 January, "The significant level at 1.0850 may act as immediate resistance for the EUR/USD pair. ", "The 14-day Relative Strength Index (RSI) for the EUR/USD pair lies below the 50 mark, indicating a bearish momentum in the market. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com